Monday, July 24, 2023 1:33:21 PM
Recent SXTP News
- 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required • GlobeNewswire Inc. • 05/02/2024 11:59:00 AM
- 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis • GlobeNewswire Inc. • 04/03/2024 11:58:00 AM
- 60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 • GlobeNewswire Inc. • 03/14/2024 11:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:00:34 PM
- 60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris • GlobeNewswire Inc. • 02/20/2024 12:59:00 PM
- 60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer • GlobeNewswire Inc. • 02/08/2024 12:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 08:33:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 08:31:40 PM
- WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering • PR Newswire (US) • 01/31/2024 05:00:00 PM
- 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering • GlobeNewswire Inc. • 01/31/2024 04:15:00 PM
- WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering • PR Newswire (US) • 01/30/2024 02:45:00 PM
- 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering • GlobeNewswire Inc. • 01/30/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/30/2024 05:15:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:01:11 PM
- 60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting • GlobeNewswire Inc. • 01/22/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 07:56:53 PM
- 60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements • GlobeNewswire Inc. • 01/16/2024 12:59:00 PM
- 60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024 • GlobeNewswire Inc. • 12/26/2023 12:59:00 PM
- 60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease • GlobeNewswire Inc. • 11/15/2023 12:29:00 PM
- 60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston • GlobeNewswire Inc. • 10/19/2023 12:31:00 PM
- 60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases • GlobeNewswire Inc. • 10/12/2023 08:16:00 PM
- 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements • GlobeNewswire Inc. • 09/18/2023 08:16:00 PM
- 60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 11:31:00 AM
- 60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity • GlobeNewswire Inc. • 08/30/2023 11:32:00 AM
- 60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria • GlobeNewswire Inc. • 08/22/2023 11:31:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM